GVS (GVS) investor relations material

Executive summary

• Consolidated revenue reached €215.0 million in H1 2026, up 3.3% at constant exchange rates, but nearly flat year-over-year at current rates, driven by volume and pricing improvements.

• Adjusted/normalised EBITDA rose 2.2% to €55.4 million, with margin expanding to 25.7%, up 62 basis points from H1 2025.

• Adjusted net income was €23.8 million (11.1% margin), impacted by FX gains and higher depreciation; reported net profit was €23.4 million, up sharply from H1 2025.

• All divisions posted positive organic growth at constant FX, with Safety and Transfusion Medicine leading; MedTech core business showed low single-digit growth.

• Profit before tax from recurring activities reached €39.0 million, up from €12.4 million in H1 2025.

Financial highlights

• Revenue from contracts with customers was €215.0 million for H1 2026.

• Adjusted EBITDA margin increased by 62 basis points to 25.7% compared to H1 2025.

• Adjusted EBIT was €37.5 million, down 5.2% year-over-year due to higher depreciation and amortisation.

• Net financial debt stood at €239.3 million, with a leverage ratio of 2.2x.

• Cash and cash equivalents at period end were €92.5 million, up from €62.0 million at June 2025.

Outlook and guidance

• 2026 guidance confirmed: low single-digit revenue growth at constant FX, 20–50 bps EBITDA margin expansion, and leverage ratio targeted at 1.8x by year-end (excluding treasury share/tender offer impact).

• New 2026–2028 business plan to be presented in September 2026.

• Strategic focus includes MedTech sub-division, Transfusion Medicine growth, Life Sciences expansion, Safety product roll-out, and Mobility stabilization.

• No specific concerns for Q3/Q4, but prudence maintained due to geopolitical uncertainties.